CD8A and metastatic melanoma: Administration of IL‐2 causes a transient increase in absolute lymphocyte counts, which has been associated with tumor response in metastatic melanoma.28 IL‐7 can also be used to increase lymphocytes (peripheral CD4+ and CD8+ T cells), resulting in immunomodulatory effects on T cells.29